Biomarkers for therapeutic efficacy

European Journal of Cancer, Supplement

Volumn 5, Issue 5, 2007, Pages 129-142

  Brünner, Nils ^a   Vang Nielsen, Kirsten ^b   Offenberg, Hanne ^a   Sweep, Fred C G J ^c   Martens, John ^d   Foekens, John ^d   Folprecht, Gunnar ^e   Lutz, Manfred P ^f   Mechetner, Eugene ^g,h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f Department of Medical Gastroenterology ^*  (Germany)

^g Oncotech Inc   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GELATINASE B; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN BAD; PROTEIN KINASE B; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALOPECIA; ARTICLE; BREAST CANCER; CANCER; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ERBB2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TOP2A GENE;

EID: 35449008458     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70033-2     Document Type: Article

References (85)

1. Hanahan D., and Weinberg R. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Nielsen K., Müller S., Poulsen T., Gabs S., and Schonau A. Combined Use of PNA and DNA for Fluorescence In Situ Hybridization (FISH). In: Nielsen P. (Ed). Peptide nucleic acids: protocols and applications. 2nd edition (2004), Horizon Bioscience, Norfolk 227-260
3. Olsen K., Knudsen H., Rasmussen B., et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43 (2004) 35-42
4. Slamon D., Clark G., Wong S., Levin W., Ullrich A., and McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
5. Slamon D., Godolphin W., Jones L., et al. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
6. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. J Med 344 (2001) 783-792
7. Wolff A., Hammond M., Schwartz J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007) 18
8. Coutts J., Plumb J., Brown R., and Keith W. Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer 68 (1993) 793-800
9. Withoff S., Keith W., Knol A., et al. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74 (1996) 502-507
10. Knoop A., Knudsen H., Balslev E., et al. TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). In: ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) 532 [June 20 Supplement]
11. Knoop A., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
12. Mueller R., Parkes R., Andrulis I., and O'Malley F. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39 (2004) 288-297
13. Callagy G., Pharoah P., Chin S., et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205 (2005) 388-396
14. Amler L., Goddard A., and Hillan K. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol 70 (2005) 483-488
15. Hirsch F., Varella-Garcia M., Bunn P., et al. Molecular predictors of outcome with gefitinib in a phase III placebo- controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
16. Tusher V., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98 (2001) 5116-5121
17. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 57 (1995) 289-300
18. In: Cox D., and Oakes D. (Eds). Analysis of survival data (1984), Chapman and Hall, New York
19. In: Johnson R., and Wichern D. (Eds). Applied multivariate statistical analysis (1988), Prentice Hall, New Jersey
20. In: Vapnik V. (Ed). The nature of statistical learning theory (1995), Springer-Verlag, Berlin
21. In: Bishop C. (Ed). Neural networks for pattern recognition (1995), Clarendon Press, Oxford
22. Eisen M., Spellman P., Brown P., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95 (1998) 14863-14868
23. Perou C., Sorlie T., Eisen M., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
24. Sorlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
25. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423
26. Rouzier R., Perou C., Symmans W., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
27. Jansen M., Foekens J., van Staveren I., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 (2005) 732-740
28. Chang J., Wooten E., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
29. Hess K., Anderson K., Symmans W., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
30. Thuerigen O., Schneeweiss A., Toedt G., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24 (2006) 1839-1845
31. Smid M., Wang Y., Klijn J., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24 (2006) 2261-2267
32. Minn A., Gupta G., Siegel P., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
33. Minn A., Kang Y., Serganova I., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115 (2005) 44-55
34. Van 't Veer L., Dai H., van de Vijver M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
35. van de Vijver M., He Y., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
36. Chang H., Nuyten D., Sneddon J., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102 (2005) 3738-3743
37. Yu K., Lee C., Tan P., et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 64 (2004) 2962-2968
38. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
39. Wang Y., Klijn J., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
40. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
41. Ma X., Wang Z., Ryan P., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
42. Goetz M., Suman V., Ingle J., et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12 (2006) 2080-2087
43. Ma X., Hilsenbeck S., Wang W., et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24 (2006) 4611-4619
44. Foekens J., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node- negative primary breast cancer. J Clin Oncol 24 (2006) 1665-1671
45. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
46. Desmedt C, Piette F, Loi S, et al. Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-center independent validation series. Clin Cancer Res, in press.
47. Davidsen M., Wurtz S., Romer M., et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy- induced apoptosis. Br J Cancer 95 (2006) 1114-1120
48. Würtz S., Schrohl A., Sorensen N., et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12 (2005) 215-227
49. Guedez L., Stetler-Stevenson W., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102 (1998) 2002-2010
50. Guedez L., Courtemanch L., and Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 92 (1998) 1342-1349
51. Jung K., Liu X., Chirco R., Fridman R., and Kim H. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25 (2006) 3934-3942
52. Liu X., Bernardo M., Fridman R., and Kim H. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278 (2003) 40364-40372
53. Schrohl A., Meijer-van Gelder M., Holten-Andersen M., et al. Primary tumor levels of tissue inhibitor of metalloproteinases- 1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12 (2006) 7054-7058
54. Sørensen N., Byström P., Christensen I., et al. Plasma Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) is significantly associated with objective response and survival in patients with metastatic colorectal cancer receiving first line treatment with irinotecan in combination with 5FU and Folinic acid. Clin Cancer Res 13 14 (2007) 4117-4122
55. Lipton A., Ali S., Leitzel K., et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109 (2007) 1933-1939
56. Thaysen-Andersen M., Thøgersen I., Nielsen H., et al. Rapid and individual-specific glycoprofiling of the low- abundant N-glycosylated protein tissue inhibitor of metalloproteinases-1. Mol Cellular Proteomics 6 (2007) 638-647
57. Usher PA, Sieuwerts AM, Bartels A, et al. Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue. Molecular Oncology, in press.
58. Sieuwerts A., Usher P., Meijer-van Gelder M., et al. Concentrations of Tissue Inhibitor of Metalloproteinses-1 (TIMP-1) mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 53 7 (2007) 1280-1288 [Epub 2007 May 3.].
59. Black M., and Spear F. Effects of cancer chemotherapeutic agents on dehydrogenase activity of human cancer tissue in vitro. Am J Clin Path 23 (1953) 218-227
60. Salmon S., Hamburger A., Soehnlen B., Durie B., Alberts D., and Moon T. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298 (1978) 1321-1325
61. Clark G., and Von Hoff D. Quality control of a multicenter human tumor cloning system, The Southwest Oncology Group experience. In: Salmon S., and Trent J. (Eds). Human tumor cloning (1984), Grune & Straton Ltd. 255-265
62. Kern D., and Weisenthal L. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82 (1990) 582-588
63. Mehta R., Bornstein R., Yu I., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66 (2001) 225-237
64. Holloway R., Mehta R., Finkler N., et al. Association between in vitro platinum resistance in the EDR Assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87 (2002) 8-16
65. DeVita V. In: DeVita V., and Rosenberg S. (Eds). Cancer: principles and practice of oncology. 5th edition (1997), Lippincott-Raven Publishers 345
66. Kern D. Tumor chemosensitivity and chemoresistance assays. Cancer 79 (1997) 1447-1450
67. Fruehauf J., and Alberts D. Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res 161 (2003) 126-145
68. Alberts D., Dorr R., Wunz T., et al. In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs. Anticancer Drugs 2 (1991) 69-77
69. Fruehauf J., and Bosanquet A. In vitro determination of drug response: a discussion of clinical applications. PPO Updates. Principles Pract Oncol 7 (1993) 1-17
70. Mehta R., Bornstein R., Yu I., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66 (2001) 225-237
71. Parker R., Fruehauf J., Mehta R., Filka E., and Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66 (2004) 365-375
72. Loizzi V., Chan J., Osann K., Cappuccini F., DiSaia P., and Berman M. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189 (2003) 1301-1307
73. Sweep F., Fritche H., Gion M., Klee G., and Schmitt M. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research. An EORTC-NCI working group report. Int J Oncol 23 (2003) 1715-1726
74. Hayes D., Bast R., Desc C., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88 (1996) 1456-1466
75. McGuire W., and Clark G. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326 (1992) 1756-1761
76. Geurts-Moespot J., Leake R., Benraad T., and Sweep C. Twenty years of experience with the steroid receptor External Quality Assessment program - the paradigm for tumour biomarker EQA studies (review). Int J Oncol 17 (2000) 13-22
77. Sweep C., and Geurts-Moespot J. EORTC external quality assurance program for ER and PgR measurements: trial 1998/1999. Int J Biol Markers 15 (2000) 62-69
78. Simmonds P. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321 (2000) 531-535
79. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
80. Douillard J., Cunningham D., Roth A., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
81. Köhne C., Van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional 5-fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. EORTC Gastrointestinal Group Study 40986. J Clin Oncol 23 (2005) 4856-4865
82. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
83. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
84. Grothey A, Deschler B, Kroening H, et al. Bolus 5-Fluorouracil (5-FU)/Folinic acid (FA) (Mayo) vs. weekly high dose 24H 5-FU infusion/FA+ Oxaliplatin (OXA) in advanced colorectal cancer (CRC): Results of a phase III study. Proceedings of the American Society of Clinical Oncology; 2001.
85. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 15 (2004) 229-237